The insider selling is routine in both proportionality and pattern — CEO Rothblatt regularly exercises options and sells shares for liquidity. The cluster does not add incremental bearish information beyond the already-reported Q2 revenue miss. Monitor the next earnings call for Tyvaso DPI growth trajectory and ralinepag/nebulized Tyvaso IPF NDA updates as the real catalysts.
Price Chart
Executive Summary
CEO Martine Rothblatt sold ~$7.1M in open-market shares over two days (Aug 12-13), exercising options at $135.42 and immediately selling the shares near $500-$520. EVP Paul Mahon also sold $167K on Aug 6. The cluster follows a Q2 earnings miss (revenue -2% YoY, below consensus) reported 10 days prior. While the CEO's sales are partially option-exercise-related, the timing and magnitude — ~$7.1M from the CEO alone, or ~0.03% of market cap — are modest relative to the $21.4B market cap, making this a routine liquidity/compensation event rather than a bearish signal. The historical calibration shows prior neutral reports on UTHR have underperformed, but this cluster's small proportionality and the CEO's known option-exercise pattern suggest limited incremental information.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold ~$7.1M in open-market shares on Aug 12-13, exercising 28,500 options at $135.42 and selling the resulting shares at $500-$520.
- EVP Paul Mahon sold 320 shares for $167K on Aug 6.
- Total cluster value of ~$7.3M represents ~0.03% of UTHR's $21.4B market cap — well below the 0.1% materiality threshold.
- The cluster follows Q2 2026 earnings (Aug 5) where revenue of $783.3M missed the $804.6M consensus, though EPS of $7.27 beat estimates.
- CEO's sales are consistent with a typical option-exercise-and-sell pattern for tax/compensation purposes, not a directional bearish signal.
Financial Impact
CEO sold ~$7.1M in open-market shares; EVP sold $167K; total cluster ~$7.3M (0.03% of market cap)
Risk Factors
- Continued Tyvaso franchise erosion (nebulized Tyvaso -18% YoY) could pressure revenue growth
- Competitive headwinds in inhaled prostacyclin class may limit Tyvaso DPI market share gains
- Pipeline setbacks for ralinepag or nebulized Tyvaso IPF could remove upside optionality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786774470943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access